Q-omics provides the consensus-scored ZNF445 profile across patient tissues and cancer cell-line models. ZNF445 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF445 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ZNF445 RNA expression shows 21,886 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where ZNF445 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF445 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF445 survival associations across molecular data types. ZNF445 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF445 RNA expression–survival associations across cancer types. High ZNF445 expression shows unfavorable associations in ACC and LIHC, but favorable associations in UCS, KIRC, HNSC and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .014). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF445 RNA expression.
This table summarizes ZNF445 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF445. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF445 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LIHC, CHOL and COAD. The KIRC box plot shows higher ZNF445 RNA expression in normal versus tumor tissue (log2 FC = −0.524, t-test p < 0.001).
This table shows molecular features associated with ZNF445 in patient tissues and cancer cell lines. In patient samples, ZNF445 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF445 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
